Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Guidelines for the management of chronic heart failure
Najah Hadi
, Jan Fedacko
, Ram B. Singh
, Galaleldin Nagib Elkilany
, Osama Elmaraghi
, Ehab Hamdy
, Krasimira Hristova
, Saibal Chakravorty
, Lyudemila Shogenova
, Jan Slezak
, Amitabh Yaduvanshi
, Meenakshi Jain
, Ashok K. Shukla
,
Germaine Cornelissen
Physiology
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Guidelines for the management of chronic heart failure'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chronic Heart Failure
100%
Angiotensin Receptor-neprilysin Inhibitor
100%
Heart Failure
80%
Angiotensin-converting Enzyme Inhibitor (ACEi)
80%
Heart Failure with Preserved Ejection Fraction (HFpEF)
60%
Angiotensin Receptor Blockers
60%
Reduced Ejection Fraction
60%
Drug Therapy
40%
Heart Failure Management
40%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
40%
Pathophysiology
20%
Acute Decompensated Heart Failure
20%
Pharmacotherapy
20%
Beta-blockers
20%
Autophagy
20%
Acute Myocardial Infarction
20%
Cardiomyocytes
20%
Novel Mechanism
20%
Patients with Heart Failure
20%
First-line Therapy
20%
Calcium Handling
20%
Behavioral Factors
20%
Left Ventricular Ejection Fraction
20%
Lifestyle Modification
20%
Therapy Optimization
20%
Heart Failure Treatment
20%
Therapy Initiation
20%
Lifestyle Recommendations
20%
Interesting Area
20%
Patients with Coronary Artery Disease
20%
Epicardial Fat
20%
New Trial
20%
Intravenous Iron
20%
Mineralocorticoid Receptor Antagonists
20%
Myocardial Energy Metabolism
20%
Quadruple Therapy
20%
Anemia Treatment
20%
Therapy Options
20%
Rapid Optimization
20%
Canadian Guidelines
20%
Opportunities for Improvement
20%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Angiotensin Receptor
71%
Enkephalinase Inhibitor
71%
Dipeptidyl Carboxypeptidase Inhibitor
57%
Pharmacotherapy
42%
Angiotensin Receptor Antagonist
42%
Iron
28%
Heart Failure with Preserved Ejection Fraction
14%
Heart Failure with Reduced Ejection Fraction
14%
Beta Adrenergic Receptor Blocking Agent
14%
Acute Heart Infarction
14%
Coronary Artery Disease
14%
Disease Predisposition
14%
Acute Heart Failure
14%
Mineralocorticoid Antagonist
14%
Sodium Glucose Cotransporter 2 Inhibitor
14%
Pathophysiology
14%
Anemia
14%
Diseases
14%
sodium glucose cotransporter-2 inhibitors
14%